PhenoNet Cleared By FDA To Begin Phase 3 Trial Of Inhaled Alzheimer's Drug&nbsp;PhenoNet has received FDA clearance to begin a Phase 3 trial of PHENOGENE-1A, an inhaled formulation of cromolyn sodium, an asthma drug with decades of safety data. Unlike most Alzheimer's therapies, which target only APOE4 gene carriers, this ~648-person trial stratifies both carriers and non-carriers by genotype, testing whether reducing amyloid aggregation, inflammation, and microglial dysfunction can benefit a broader Alzheimer's population than current treatments reach. Host Dave Asprey explains why this genotype-inclusive design challenges the field's narrow focus on APOE4 carriers, and what it means for families with Alzheimer's history who don't carry the gene.&nbsp;Sources:&nbsp;<ul><li><a href="https://www.morningstar.com/news/business-wire/20260813649121/phenonet-cleared-by-fda-to-begin-phase-3-trial-of-inhaled-phenogene-1a-in-early-alzheimers-disease" rel="noopener noreferrer" target="_blank">https://www.morningstar.com/news/business-wire/20260813649121/phenonet-cleared-by-fda-to-begin-phase-3-trial-of-inhaled-phenogene-1a-in-early-alzheimers-disease</a>&nbsp;</li><li><a href="https://www.businesswire.com/news/home/20260813649121/en/" rel="noopener noreferrer" target="_blank">https://www.businesswire.com/news/home/20260813649121/en/</a>&nbsp;</li><li><a href="https://www.phenonet.us/" rel="noopener noreferrer" target="_blank">https://www.phenonet.us</a>&nbsp;</li></ul>~~~University Of Zurich Researchers Discover The Adult Brain Can Repair Itself Better Than Believed&nbsp;Researchers at the University of Zurich identified a population of "regenerative astrocytes" in living mouse brains that repair damaged tissue through a previously unknown mechanism: dividing cells send newly formed nuclei traveling across long cellular extensions to repopulate injured regions and rebuild the astrocyte network. The discovery overturns the long-standing assumption that adult brains have limited capacity to replace lost astrocytes after injury or autoimmune disease. Host Dave Asprey unpacks why this finding reframes brain injury recovery as something the body may already be equipped to handle, and what the newly identified genetic pathways could mean for future regenerative therapies.&nbsp;Sources:&nbsp;<ul><li><a href="https://www.news.uzh.ch/en/articles/media/2026/regenerative-astrocytes.html" rel="noopener noreferrer" target="_blank">https://www.news.uzh.ch/en/articles/media/2026/regenerative-astrocytes.html</a>&nbsp;</li><li><a href="https://www.sciencedaily.com/releases/2026/08/260812015158.htm" rel="noopener noreferrer" target="_blank">https://www.sciencedaily.com/releases/2026/08/260812015158.htm</a>&nbsp;</li><li><a href="https://www.eurekalert.org/news-releases/1139114" rel="noopener noreferrer" target="_blank">https://www.eurekalert.org/news-releases/1139114</a>&nbsp;</li><li><a href="https://www.nature.com/articles/s41593-026-02354-5" rel="noopener noreferrer" target="_blank">https://www.nature.com/articles/s41593-026-02354-5</a>&nbsp;</li></ul>~~~Sheep's Wool-Derived Keratin Outperforms Collagen In Bone Regeneration Study&nbsp;Researchers at King's College London developed a keratin scaffold from sheep's wool, a farming industry waste product, and tested it against collagen, the current gold standard, in rats with non-healing skull defects. While collagen produced more total bone volume, the keratin scaffold generated bone that was more structurally organized and closer to natural bone architecture, while remaining stable and integrating cleanly with surrounding tissue. Host Dave Asprey explains why bone quality, not just quantity, matters for weight-bearing repair, and why a cheaper, more sustainable material outperforming the standard is a bigger deal than it sounds.&nbsp;Sources:&nbsp;<ul><li><a href="https://medicalxpress.com/news/2026-04-scientists-wool-bone-material.html" rel="noopener noreferrer" target="_blank">https://medicalxpress.com/news/2026-04-scientists-wool-bone-material.html</a>&nbsp;</li><li><a href="https://www.sciencedaily.com/releases/2026/08/260812015210.htm" rel="noopener noreferrer" target="_blank">https://www.sciencedaily.com/releases/2026/08/260812015210.htm</a>&nbsp;</li><li><a href="https://www.ivanhoe.com/news_flash/scientists-turn-sheeps-wool-into-a-material-that-helps-regrow-bone-click-here/" rel="noopener noreferrer" target="_blank">https://www.ivanhoe.com/news_flash/scientists-turn-sheeps-wool-into-a-material-that-helps-regrow-bone-click-here/</a>&nbsp;</li></ul>~~~Oral GLP-1 Pill Aleniglipron Shows 12% Weight Loss In Phase 2b Trial&nbsp;Structure Therapeutics' oral small-molecule GLP-1 receptor agonist, aleniglipron, produced up to 12.1% weight loss at 36 weeks in a 230-person Phase 2b trial, with no apparent plateau and continued loss to 16% in the open-label extension, putting an oral pill in the same efficacy range as injectable GLP-1 drugs like Wegovy and Ozempic. Host Dave Asprey weighs the compliance advantage of an oral option against his ongoing concerns about muscle loss, rebound weight gain, and the fact that GLP-1 drugs treat a symptom rather than the underlying metabolic cause.&nbsp;Sources:&nbsp;<ul><li><a href="https://pubmed.ncbi.nlm.nih.gov/42249138/" rel="noopener noreferrer" target="_blank">https://pubmed.ncbi.nlm.nih.gov/42249138/</a>&nbsp;</li><li><a href="https://www.nature.com/articles/s41591-026-04476-6" rel="noopener noreferrer" target="_blank">https://www.nature.com/articles/s41591-026-04476-6</a>&nbsp;</li><li><a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-publication-nature-medicine/" rel="noopener noreferrer" target="_blank">https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-announces-publication-nature-medicine/</a>&nbsp;</li><li><a href="https://www.fiercebiotech.com/biotech/structure-touts-16-weight-loss-aleniglipron-highest-efficacy-oral-glp-1" rel="noopener noreferrer" target="_blank">https://www.fiercebiotech.com/biotech/structure-touts-16-weight-loss-aleniglipron-highest-efficacy-oral-glp-1</a>&nbsp;</li></ul>~~~Study Finds 150 Minutes Of Weekly Exercise Falls Far Short Of Real Heart Protection&nbsp;A Macao Polytechnic University analysis of over 17,000 UK Biobank participants found that the standard 150-minute weekly exercise guideline only reduces cardiovascular risk by 8-9%, while achieving a substantial risk reduction of over 30% requires 560-610 minutes a week, three to four times current recommendations. Only 12% of participants hit that higher threshold. Host Dave Asprey breaks down why public health minimums are a floor, not an optimization target, and what listeners serious about cardiovascular protection should actually be aiming for.&nbsp;Sources:&nbsp;<ul><li><a href="https://medicalxpress.com/news/2026-05-real-heart-weekly-climbs-current.html" rel="noopener noreferrer" target="_blank">https://medicalxpress.com/news/2026-05-real-heart-weekly-climbs-current.html</a>&nbsp;</li><li><a href="https://www.medicalnewstoday.com/articles/560-610-minutes-weekly-exercise-lower-cardiovascular-risk-heart-health" rel="noopener noreferrer" target="_blank">https://www.medicalnewstoday.com/articles/560-610-minutes-weekly-exercise-lower-cardiovascular-risk-heart-health</a>&nbsp;</li><li><a href="https://bjsm.bmj.com/content/early/2026/05/19/bjsports-2025-111351" rel="noopener noreferrer" target="_blank">https://bjsm.bmj.com/content/early/2026/05/19/bjsports-2025-111351</a>&nbsp;</li></ul>~~~New Research Clarifies The Mechanism Behind IV Vitamin C's Anti-Cancer Effect&nbsp;Decades after Linus Pauling's high-dose vitamin C claims were dismissed following failed oral-dose trials, researchers have clarified that Pauling had the mechanism right and the delivery method wrong: IV vitamin C bypasses gut absorption limits to reach plasma concentrations up to 100 times higher than oral dosing, generating hydrogen peroxide that is selectively toxic to cancer cells due to their lower catalase levels. A 2024 University of Iowa study found IV vitamin C combined with chemotherapy doubled overall survival in advanced pancreatic cancer patients. Host Dave Asprey reflects on how this vindicates a decades-old idea that was dismissed for the wrong reasons, and what it means for anyone facing a cancer diagnosis.&nbsp;Sources:&nbsp;<ul><li><a href="https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.01182/full" rel="noopener noreferrer" target="_blank">https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.01182/full</a>&nbsp;</li><li><a href="https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq" rel="noopener noreferrer" target="_blank">https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq</a>&nbsp;</li><li><a href="https://medicine.uiowa.edu/news/2024/11/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic-cancer" rel="noopener noreferrer" target="_blank">https://medicine.uiowa.edu/news/2024/11/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic-cancer</a>&nbsp;</li></ul>&nbsp;This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want the latest breakthroughs in neurodegenerative disease, regenerative medicine, metabolic health, and cancer therapeutics, translated into what actually matters for your biology right now. Host Dave Asprey connects clinical trial data, mechanistic research, and decades of context into practical frameworks for taking control of your own health decisions.&nbsp;New episodes every Tuesday, Thursday, Friday, and Sunday.&nbsp;Keywords:&nbsp;PhenoNet PHENOGENE-1A, inhaled cromolyn Alzheimer's, APOE4 genotype Alzheimer's trial, regenerative astrocytes brain repair, University of Zurich brain regeneration, adult neuroplasticity, keratin bone scaffold, sheep's wool regenerative medicine, collagen vs keratin bone repair, aleniglipron oral GLP-1, Structure Therapeutics weight loss drug, oral semaglutide alternative, exercise minutes cardiovascular risk, 150 minutes exercise guideline, Macao Polytechnic University heart study, IV vitamin C cancer, Linus Pauling vitamin C, ascorbate hydrogen peroxide cancer cells, integrative oncology, biohacking news 2026, &nbsp;Thank you to our sponsors!&nbsp;&nbsp;- Visit&nbsp;<a href="http://www.myvitalc.com/davesfav" rel="noopener noreferrer" target="_blank">www.myvitalc.com/davesfav</a>&nbsp;to unlock Dave’s discount&nbsp;- Neuronic | Go to&nbsp;<a href="http://www.neuronic.online/" rel="noopener noreferrer" target="_blank">www.neuronic.online</a>&nbsp;Code DAVE for $100 off&nbsp;- iRestore | Reverse hair loss at&nbsp;<a href="http://www.irestore.com/DAVE" rel="noopener noreferrer" target="_blank">www.irestore.com/DAVE</a>&nbsp;and get exclusive savings on the iRestore Elite, use code DAVE&nbsp;Resources:&nbsp;&nbsp;&nbsp;• Get My 2026 Clean Nicotine Roadmap | Enroll for free at <a href="https://daveasprey.com/2026-clean-nicotine-roadmap/" rel="noopener noreferrer" target="_blank">https://daveasprey.com/2026-clean-nicotine-roadmap/</a>&nbsp;• Get My 2026 Biohacking Trends Report: <a href="https://daveasprey.com/2026-biohacking-trends-report/" rel="noopener noreferrer" target="_blank">https://daveasprey.com/2026-biohacking-trends-report/</a>&nbsp;• Dave Asprey's Latest News | Go to <a href="https://daveasprey.com/" rel="noopener noreferrer" target="_blank">https://daveasprey.com/</a> to join Inside Track today.&nbsp;&nbsp;• Danger Coffee: <a href="https://dangercoffee.com/discount/dave15" rel="noopener noreferrer" target="_blank">https://dangercoffee.com/discount/dave15</a>&nbsp;&nbsp;&nbsp;• My Daily Supplements: <a href="https://www.shopsuppgradelabs.com/discount/DAVE15" rel="noopener noreferrer" target="_blank">SuppGrade Labs</a> (15% Off)&nbsp;&nbsp;&nbsp;• Favorite Blue Light Blocking Glasses: <a href="https://truedark.com/?coupon-code=DAVEASPREY15&sc-page=shop" rel="noopener noreferrer" target="_blank">TrueDark</a> (15% Off)&nbsp;&nbsp;&nbsp;• Dave Asprey’s BEYOND Conference: <a href="https://beyondconference.com/" rel="noopener noreferrer" target="_blank">https://beyondconference.com</a>&nbsp;&nbsp;&nbsp;• Dave Asprey’s New Book – Heavily Meditated: <a href="https://daveasprey.com/heavily-meditated" rel="noopener noreferrer" target="_blank">https://daveasprey.com/heavily-meditated</a>&nbsp;&nbsp;• Join My Substack (Live Access To Podcast Recordings): <a href="https://substack.daveasprey.com/" rel="noopener noreferrer" target="_blank">https://substack.daveasprey.com/</a>&nbsp;• Upgrade Labs: <a href="https://upgradelabs.com/" rel="noopener noreferrer" target="_blank">https://upgradelabs.com</a>&nbsp;&nbsp;&nbsp;Timestamps:&nbsp;00:00 – Alzheimer's Drug Trial&nbsp;01:43 – Brain Repair Cells&nbsp;03:07 – Keratin Bone Scaffolds&nbsp;04:45 – Oral GLP-1 Pill&nbsp;05:59 – Minimum Effective Exercise&nbsp;07:26 – IV Vitamin C Revisited&nbsp;08:12 – Vitamin C Cancer Trial&nbsp;09:30 – Takeaway&nbsp;See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Depressing Fruit, Vitamin (C)ancer, Sheep Wool, Oral GLP-1s, Endless Exercise, and more : 1519

The Human Upgrade: Biohacking for Longevity & Performance

AI Chapters

AI Insights

Reviews